BACKGROUND: The logopenic variant of primary progressive aphasia (lvPPA) manifests due to a breakdown of the language network with prominent hypometabolism of the left temporoparietal region. LvPPA is strongly associated with amyloid deposition, yet there is question as to whether it is a homogeneous clinical entity. OBJECTIVE: This study investigated whether differences in temporoparietal metabolic patterns on 18F fludeoxyglucose positron emission tomography (FDG-PET) could elucidate brain regions preferentially affected in lvPPA. METHOD: We used differences in FDG-PET metabolic z-scores relative to controls for means of left lateral temporal, left inferior parietal, and left superior parietal regions to classify 53 amyloid-positive lvPPA patients into temporal, parietal, or temporoparietal predominate groups. Clinical features and FDG-PET regions of hypometabolism outside of the temporoparietal region were then compared across the three groups; the latter using statistical parametric mapping. RESULTS: Of the 53 lvPPA patients, 15 were classified as temporal, 14 as temporoparietal, and 22 as parietal predominate. There were no significant differences between the groups on demographic measures, language evaluation, or apolipoprotein E genotype. Compared to the other two groups, individuals with the parietal predominate pattern had extensive hypometabolism in left frontal lobe and the precuneus. Furthermore, this group had greater behavioral dyscontrol and deficits in executive function, visuospatial skills, visual memory retention, working memory, and cognitive flexibility (Bonferronip < 0.05). CONCLUSIONS: This study demonstrates that there is clinical heterogeneity within amyloid-positive lvPPA. Patients with lvPPA with predominant parietal hypometabolism, unlike those with temporal or temporoparietal predominant hypometabolism, demonstrated widespread cognitive and behavioral changes.
BACKGROUND: The logopenic variant of primary progressive aphasia (lvPPA) manifests due to a breakdown of the language network with prominent hypometabolism of the left temporoparietal region. LvPPA is strongly associated with amyloid deposition, yet there is question as to whether it is a homogeneous clinical entity. OBJECTIVE: This study investigated whether differences in temporoparietal metabolic patterns on 18F fludeoxyglucose positron emission tomography (FDG-PET) could elucidate brain regions preferentially affected in lvPPA. METHOD: We used differences in FDG-PET metabolic z-scores relative to controls for means of left lateral temporal, left inferior parietal, and left superior parietal regions to classify 53 amyloid-positive lvPPApatients into temporal, parietal, or temporoparietal predominate groups. Clinical features and FDG-PET regions of hypometabolism outside of the temporoparietal region were then compared across the three groups; the latter using statistical parametric mapping. RESULTS: Of the 53 lvPPApatients, 15 were classified as temporal, 14 as temporoparietal, and 22 as parietal predominate. There were no significant differences between the groups on demographic measures, language evaluation, or apolipoprotein E genotype. Compared to the other two groups, individuals with the parietal predominate pattern had extensive hypometabolism in left frontal lobe and the precuneus. Furthermore, this group had greater behavioral dyscontrol and deficits in executive function, visuospatial skills, visual memory retention, working memory, and cognitive flexibility (Bonferronip < 0.05). CONCLUSIONS: This study demonstrates that there is clinical heterogeneity within amyloid-positive lvPPA. Patients with lvPPA with predominant parietal hypometabolism, unlike those with temporal or temporoparietal predominant hypometabolism, demonstrated widespread cognitive and behavioral changes.
Authors: M L Gorno-Tempini; A E Hillis; S Weintraub; A Kertesz; M Mendez; S F Cappa; J M Ogar; J D Rohrer; S Black; B F Boeve; F Manes; N F Dronkers; R Vandenberghe; K Rascovsky; K Patterson; B L Miller; D S Knopman; J R Hodges; M M Mesulam; M Grossman Journal: Neurology Date: 2011-02-16 Impact factor: 9.910
Authors: Rik Ossenkoppele; Yolande A L Pijnenburg; David C Perry; Brendan I Cohn-Sheehy; Nienke M E Scheltens; Jacob W Vogel; Joel H Kramer; Annelies E van der Vlies; Renaud La Joie; Howard J Rosen; Wiesje M van der Flier; Lea T Grinberg; Annemieke J Rozemuller; Eric J Huang; Bart N M van Berckel; Bruce L Miller; Frederik Barkhof; William J Jagust; Philip Scheltens; William W Seeley; Gil D Rabinovici Journal: Brain Date: 2015-07-02 Impact factor: 13.501
Authors: Hugo Botha; Joseph R Duffy; Jennifer L Whitwell; Edythe A Strand; Mary M Machulda; Christopher G Schwarz; Robert I Reid; Anthony J Spychalla; Matthew L Senjem; David T Jones; Val Lowe; Clifford R Jack; Keith A Josephs Journal: Cortex Date: 2015-05-27 Impact factor: 4.027
Authors: Keith A Josephs; Joseph R Duffy; Edythe A Strand; Mary M Machulda; Matthew L Senjem; Ankit V Master; Val J Lowe; Clifford R Jack; Jennifer L Whitwell Journal: Brain Date: 2012-03-01 Impact factor: 13.501
Authors: Jonathan D Rohrer; Gerard R Ridgway; Sebastian J Crutch; Julia Hailstone; Johanna C Goll; Matthew J Clarkson; Simon Mead; Jonathan Beck; Cath Mummery; Sebastien Ourselin; Elizabeth K Warrington; Martin N Rossor; Jason D Warren Journal: Neuroimage Date: 2009-08-11 Impact factor: 6.556
Authors: Matthias Brendel; Jonas Schnabel; Sonja Schönecker; Leonie Wagner; Eva Brendel; Johanna Meyer-Wilmes; Marcus Unterrainer; Andreas Schildan; Marianne Patt; Catharina Prix; Nibal Ackl; Cihan Catak; Oliver Pogarell; Johannes Levin; Adrian Danek; Katharina Buerger; Peter Bartenstein; Henryk Barthel; Osama Sabri; Axel Rominger Journal: Eur J Nucl Med Mol Imaging Date: 2017-09-20 Impact factor: 9.236
Authors: Marina Buciuc; Jennifer L Whitwell; Koji Kasanuki; Jonathan Graff-Radford; Mary M Machulda; Joseph R Duffy; Edythe A Strand; Val J Lowe; Neill R Graff-Radford; Beth K Rush; Malgorzata B Franczak; Margaret E Flanagan; Matthew C Baker; Rosa Rademakers; Owen A Ross; Bernardino F Ghetti; Joseph E Parisi; Aditya Raghunathan; R Ross Reichard; Eileen H Bigio; Dennis W Dickson; Keith A Josephs Journal: Ann Neurol Date: 2020-12-17 Impact factor: 10.422
Authors: Diana Petroi; Joseph R Duffy; Andrew Borgert; Edythe A Strand; Mary M Machulda; Matthew L Senjem; Clifford R Jack; Keith A Josephs; Jennifer L Whitwell Journal: Brain Lang Date: 2020-02-27 Impact factor: 2.381
Authors: Tyler E Owens; Mary M Machulda; Joseph R Duffy; Edythe A Strand; Heather M Clark; Sarah Boland; Peter R Martin; Val J Lowe; Clifford R Jack; Jennifer L Whitwell; Keith A Josephs Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: Diana Petroi; Grant M Walker; Joseph R Duffy; Gregory S Hickok; Keith A Josephs Journal: Am J Speech Lang Pathol Date: 2021-04-19 Impact factor: 2.408
Authors: Jennifer M Harris; Jennifer A Saxon; Matthew Jones; Julie S Snowden; Jennifer C Thompson Journal: J Neuropsychol Date: 2018-02-08 Impact factor: 2.864
Authors: Siddharth Ramanan; Daniel Roquet; Zoë-Lee Goldberg; John R Hodges; Olivier Piguet; Muireann Irish; Matthew A Lambon Ralph Journal: Brain Commun Date: 2020-10-17
Authors: Siddharth Ramanan; Muireann Irish; Karalyn Patterson; James B Rowe; Maria Luisa Gorno-Tempini; Matthew A Lambon Ralph Journal: Brain Date: 2022-09-14 Impact factor: 15.255